Sitemap
Pages
News
- Evgen Pharma “cash runway in pretty good shape”
- Evgen Pharma “delighted” with cash position after promising first half
- Evgen Pharma “very busy” at start of “exciting year”
- Evgen Pharma CMO highlights “very aggressive” disease on Glioblastoma Awareness Day
- Evgen Pharma have ‘many shots at goal’, solving unmet needs in the pharmaceutical industry
- Evgen Pharma Licensing and Clinical Programme Update
- Evgen Pharma Post AGM Presentation
- Evgen Pharma presents 2022 clinical trials plans and progress with US and UK regulators
- Evgen Pharma presents at the Proactive One2One Investor Forum
- Evgen Pharma talks through clinical milestones and financial results from its 2022 full-year report
- Evgen Pharma updates on the ‘STAR’ trial for Covid-19, Glioma research and key breast cancer drug
- Evgen portfolio update on core field of cancer, ‘the R&D is entirely on plan and on budget’
- Interim Results 2022-23
- Investor Meet Company Presentation
- Investor Meet Company Presentation: Results and AGM
- Investor Meet Presentation – Proposed Acquisition of Chronos Therapeutics Ltd, Placing and Accompanying Retail Offer